Impax Laboratories — Q1 2017 Earnings Presentation
26 slides from Impax Laboratories's earnings presentation, May 10, 2017
Slide 1: First Quarter 2017 Results and Business Update
1 First Quarter 2017 Results and Business Update May 10, 2017
Slide 2: Cautionary Statement Regarding Forward Looking Statements
2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and
Slide 3: Presentation Overview
3 Presentation Overview Paul Bisaro – President & Chief Executive Officer 1Q 2017 Results Consolidation and Improvement Plan (“CIP”) Pipeline Update Bryan Reasons – Senior Vice President, Chief Financial Officer 1Q 2017 Financial Review Capital Structure Paul Bisaro Updated 2017 Financia
Slide 4: Paul Bisaro, President & CEO
4 Paul Bisaro President & CEO
Slide 5: 1Q 2017 Results
5 1Q 2017 Results $226 $198 $184 1Q16 4Q16 1Q17 $64 $37 $32 1Q16 4Q16 1Q17 $0.43 $0.16 $0.11 1Q16 4Q16 1Q17 Revenues $ millions Adjusted EBITDA $ millions Adjusted EPS Year over year results primarily impacted by significant reduction in sales of diclofenac sodium gel – down $49 million Solid gr
Slide 6: Post 1Q17 Events
6 Post 1Q17 Events April 26 - generic Vytorin® approved Immediately launched; exceeded expectations on launch acceptance Competitive multiplayer market Generics Business Update IMS NPA Weekly April 21, 2017 0% 5% 10% 15% 20% 25% 30% Share Growth April 2016 – April 2017 6% 26% 0% 10% 20% 30% 40
Slide 7: Specialty Business Update
7 • 1Q Albenza revenue impacted by higher mix of government contracting sales and prior year supply issue** • Combined anthelmintic share holding in the 42%- 45% range • Continuing to pursue Managed Medicaid contracting opportunities • 1Q revenue and TRx’s impacted by timing and seasonality • Favora
Slide 8: Consolidation and Improvement Plan
8 Consolidation and Improvement Plan Consolidating all of Generic R&D, U.S. manufacturing and packaging operations to Hayward facility Continuing previously announced closure of Middlesex manufacturing site; now includes closure of the Generic R&D site Reorganizing certain functions including
Slide 9: Consolidation and Improvement Plan
9 Consolidation and Improvement Plan Previously Announced Four New Initiatives Identified ~$45M Run-Rate Savings ~$85M Run-Rate Savings • Tech Ops and R&D Restructuring - completed 2015 • Close Philadelphia Packaging Facility - completed 2016 • Close Middlesex Manufacturing – estimated completion mi
Slide 10: Consolidation and Improvement Plan Run-Rate Savings
10 Previously Announced Initiatives ~45M Run-Rate Realized ~$20M of cost savings in 2016 Additional $12M by year-end 2017 (which annualizes to $24M) Full run-rate of ~$45M in 2018 New Initiatives ~$85M Run-Rate Limited savings impact in 2017 Full run-rate of ~$85M by year-end 2019 Total
Slide 11: Continuing to Expand Pipeline Opportunities
11 Continuing to Expand Pipeline Opportunities Generic R&D 16 14 6 5 Pending at FDA $17B Under Development $6B Solid Oral Dose Alternative Dose 22 19 # of Potential Products FTF or FTM 9 17 Specialty Pharma R&D Portfolio of 41 Products Current U.S. Brand/Generic Market of $23B IPX203 Carbidopa-Levod
Slide 12: Bryan Reasons, Chief Financial Officer
12 Bryan Reasons Chief Financial Officer
Slide 13: Generic Division 1Q 2017 Results
13 Generic Division 1Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results $ millions 1Q 2017 4Q 2016 Change 1Q/4Q 1Q 2016 Change 1Q/1Q GENERIC DIVISION Total Revenues $134.1 $139.2 (4%) $170.1 (21%) GAAP Gross Margin (6%) (127%)
Slide 14: Specialty Pharma Division 1Q 2017 Results
14 Specialty Pharma Division 1Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results $ millions 1Q 2017 4Q 2016 Change 1Q/4Q 1Q 2016 Change 1Q/1Q SPECIALTY PHARMA DIVISION Total Revenues $50.3 $59.2 (15%) $55.4 (9%) GAAP Gross Marg
Slide 15: Consolidated 1Q 2017 Results
15 Consolidated 1Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results $ millions, except per share amounts 1Q 2017 4Q 2016 Change 1Q/4Q 1Q 2016 Change 1Q/1Q EBITDA ($30.2) ($234.0) 87% $5.6 (639%) Adjusted EBITDA $31.9 $37.3 (14%
Slide 16: Capital Structure
16 Capital Structure ($ millions) Cash and Cash Equivalents $ 157 Revolver ($200) $ 0 2022 Convertible Senior Notes 600 Senior Secured Term Loan 340 Total Debt $ 940 Total Net Debt $ 783 Capital Structure as of March 31, 2017 Revised debt covenants provides additional operating flexibility Previous
Slide 17: Paul Bisaro, President & CEO
17 Paul Bisaro President & CEO
Slide 18: Updated 2017 Financial Guidance Summary
18 Updated 2017 Financial Guidance Summary Previous Guidance March 1 Updated Guidance May 10** Adjusted Gross Margin as a % of Revenues ~ 47% to 49% No Change Adjusted R&D & Patent Litigation Expense ~ $90M to $95M No Change Adjusted Selling, General & Administrative Expense ~ $190M to $195M No Chan
Slide 19: Path Forward
19 Path Forward • Impax Generics: Expand & diversify portfolio • Impax Specialty: Focus on differentiated products targeting Movement Disorders and other CNS opportunities Invest for Growth • Continue highest level of Quality • Maintain superior service levels • Deliver differentiated products to ou
Slide 20: Q&A
20 Q&A
Slide 21: ANDA Pipeline Includes Several Potential High-Value First-to-Market Opportunities
21 ANDA Pipeline Includes Several Potential High-Value First-to-Market Opportunities Source of sales data: IMS NPS Mar 2017; Pipeline data as of Apr 30, 2017; TA = tentative approval 1 Launched authorized generic in April 2016 2 Assuming final FDA approval, earliest potential launch date/timing base
Slide 22: GAAP to Adjusted Results Reconciliation
22 GAAP to Adjusted Results Reconciliation The following table reconciles total Company reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin, adjusted research and development expenses, and adjusted selling, general and administrative expenses. (Unaudi
Slide 23: GAAP to Adjusted Net Income Reconciliation
23 GAAP to Adjusted Net Income Reconciliation The following table reconciles reported net loss to adjusted net income. (Unaudited, In thousands, except per share and per share data) Refer to the First Quarter 2017 Earnings Release for an explanation of adjusted items. The sum of the individual amoun
Slide 24: GAAP to Adjusted EBITDA Reconciliation
24 GAAP to Adjusted EBITDA Reconciliation Refer to the First Quarter 2017 Earnings Release for an explanation of adjusted items. The sum of the individual amounts may not equal due to rounding. The following table reconciles reported net loss to adjusted EBITDA. (Unaudited, In thousands) March 31, D
Slide 25: Generic Division GAAP to Adjusted Results Reconciliation
25 Generic Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Generics Division reported cost of revenues and (Loss) income from operations to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income. (Unaudited, In
Slide 26: Specialty Pharma Division GAAP to Adjusted Results Reconciliation
26 Specialty Pharma Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Specialty Pharma Division reported cost of revenues and (Loss) income from operations to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted income from oper